



September 7, 2017

## **Daré Bioscience, Inc. to Present at the 19th Annual Rodman & Renshaw Global Investment Conference**

SAN DIEGO, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a healthcare company committed to the development and commercialization of innovative products in women's reproductive health, today announced that Sabrina Martucci Johnson, Chief Executive Officer and Founder, will present at the 19<sup>th</sup> Annual Rodman & Renshaw Global Investment Conference on Monday, September 11, 2017 at 12:30 p.m. Eastern Time in New York, NY. Ms. Johnson will provide a Daré overview and business update.

The presentation will be webcast live and may be accessed by visiting Daré's website at <http://ir.darebioscience.com>. A replay of the webcast will be available for 10 business days.

### **About Daré Bioscience**

Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women's reproductive health. Daré believes there is an unmet global need in women's reproductive health for new products that expand options, improve outcomes and are easy to use. Product development in women's reproductive health is fragmented creating a potential opportunity for Daré. The Company seeks to fill this gap by taking promising product candidates through clinical development and believes the team is well suited to ensure current and potential future product candidates advance and one day become commercially available to women worldwide. Daré's executive management team brings experience in global women's healthcare as well as a track record of success in prior ventures in financing, partnering, commercializing, and achieving regulatory approval for medical devices, therapeutics and diagnostics. For more information on Daré, please visit [www.darebioscience.com](http://www.darebioscience.com).

### **Forward-Looking Statements**

*This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995 regarding matters that are not historical facts, including statements relating to Daré's expectations regarding the anticipated market demands for its products, the safety and effectiveness of its products, market acceptance of Dare's products and the qualifications and expertise of Dare's management team. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation and completion of clinical trials; availability and timing of data from ongoing and future clinical trials and the results of such trials; whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals; claims of infringement and other risks relating to Daré's owned and licensed intellectual property rights, and other factors discussed in the "Risk Factors" section of Daré's Quarterly Report on Form 10-Q filed with the SEC on August 14, 2017. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. Daré specifically disclaims any obligation to update any forward-looking statements included in this press release.*

### **CONTACT:**

[innovations@darebioscience.com](mailto:innovations@darebioscience.com)

Phone: 858-926-7655

Source: Daré Bioscience

Source: Dare Bioscience, Inc.

News Provided by Acquire Media